Tian-Shu Liu (TianShu Liu, Tianshu Liu, T Liu)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 38

Top Venues

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Cancer management and research

Nature communications

Zhongshan Hospital Fudan University

Fudan University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhongshan Hospital Fudan University

China

Director :: Oncology Department

Education History

Fudan University Sep 01 2004 - Jul 31 2007

China

PHD :: zhongshan hospital

Publications

Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine 30 (7) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine 30 (7) (2024)
Xiaojing Xu, Mengling Liu, Ke Peng, Yiyi Yu, Tian-Shu Liu
Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Shu-Kui Qin, Tian-Shu Liu, Jian-Ming Xu, Qi Li, Ying Cheng, Aimar Zhang, Regina Esser, Helena Chang, Jin Li
Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer. Future oncology (London, England) (2023)
Maosen Dou, Dan Li, Mengchan Zhu, Wei Guo, Changhong Miao, Min Li, Ying Xue, Ruiping He, Nan Jiang, Di Ge, Qin Hu, Yue Shao, Yingyong Hou, Xuefei Wang, Xingxu Huang, Tian-Shu Liu, Qi Wang, Yuehong Wang, Jiayuan Sun, Weibing Wang, Yuanlin Song, Jie Hu, Qihong Huang
Quantitative analysis of a novel DNA hypermethylation panel using bronchial specimen for lung cancer diagnosis. International journal of cancer (2023)
Xiaojing Xu, Mengling Liu, Ke Peng, Yiyi Yu, Tian-Shu Liu
Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (3) (2023)
Xiaojing Xu, Mengling Liu, Ke Peng, Yiyi Yu, Tian-Shu Liu
Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (3) (2023)
Xiaojing Xu, Mengling Liu, Ke Peng, Yiyi Yu, Tian-Shu Liu
Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 (3) (2023)
Mengxuan Zhu, Erbao Chen, Shan Yu, Chen Xu, Yiyi Yu, Xin Cao, Wei Li, Pengfei Zhang, Yan Wang, Baofeng Lian, Shuirong Zhang, Yueting Qu, Lujia Huang, Weiwei Shi, Yuehong Cui, Li Qian, Tian-Shu Liu
Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach. Cancer communications (London, England) 42 (10) (2022)
Tian-Shu Liu, Yuxian Bai, Xiaoyan Lin, Wei Li, Jufeng Wang, Xiaochun Zhang, Hongming Pan, Chun-Mei Bai, Li Bai, Ying Cheng, Jingdong Zhang, Haijun Zhong, Yi Ba, Wenwei Hu, Rui-Hua Xu, Weijian Guo, Shukui Qin, Nong Yang, Jianwei Lu, Kohei Shitara, Ming Lei, Mingshun Li, Nicole Bao, Tian Chen, Lin Shen
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. International journal of cancer (2022)
Ke Peng, Feifei Zhang, Yichen Wang, Pranshu Sahgal, Tianxia Li, Jin Zhou, Xiaoyan Liang, Yanxi Zhang, Nilay S Sethi, Tian-Shu Liu, Haisheng Zhang, Adam J Bass
Development of combination strategies for Focal Adhesion Kinase inhibition in Diffuse Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Yan Li, Chen Xu, Bing Wang, Fu-Jiang Xu, Fahan Ma, Yuanyuan Qu, Dongxian Jiang, Kai Li, Jinwen Feng, Sha Tian, Xiaohui Wu, Yun-Zhi Wang, Yang Liu, Zhaoyu Qin, Yalan Liu, Jing Qin, Qi Song, Xiaolei Zhang, Akesu Sujie, Jie Huang, Tian-Shu Liu, Kuntang Shen, Jian-Yuan Zhao, Ying-Yong Hou, Chen Ding
Author Correction: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature communications 13 (1) (2022)
Yan Li, Chen Xu, Bing Wang, Fu-Jiang Xu, Fahan Ma, Yuanyuan Qu, Dongxian Jiang, Kai Li, Jinwen Feng, Sha Tian, Xiaohui Wu, Yun-Zhi Wang, Yang Liu, Zhaoyu Qin, Yalan Liu, Jing Qin, Qi Song, Xiaolei Zhang, Akesu Sujie, Jie Huang, Tian-Shu Liu, Kuntang Shen, Jian-Yuan Zhao, Ying-Yong Hou, Chen Ding
Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nature communications 13 (1) (2022)
Zhaoqing Tang, Yan Wang, Dan Liu, Xuefei Wang, Chen Xu, Yiyi Yu, Yuehong Cui, Cheng Tang, Qian Li, Jing Sun, Qian Zhang, Yuan Ji, Guifen Ma, Haojie Li, Zhenbin Shen, Kuntang Shen, Rongrong Zheng, Zhiguo Hou, Tian-Shu Liu, Jiping Wang, Yihong Sun
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nature communications 13 (1) (2022)
Yan-Jie Chen, Wei-Feng Hong, Meng-Ling Liu, Xi Guo, Yi-Yi Yu, Yue-Hong Cui, Tian-Shu Liu, Li Liang
An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis. Cell death & disease 13 (3) (2022)
Suyao Li, Qing Liu, Mengling Liu, Tian-Shu Liu
Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report. Cancer management and research 14 (2022)
Yitao Yuan, Mengling Liu, Pengcong Hou, Li Liang, Xun Sun, Lu Gan, Tian-Shu Liu
Identification of a metabolic signature to predict overall survival for colorectal cancer. Scandinavian journal of gastroenterology 56 (9) (2021)
Shu-Kui Qin, Rui-Hua Xu, Lin Shen, Jianming Xu, Yuxian Bai, Lei Yang, Yanhong Deng, Zhen-Dong Chen, Haijun Zhong, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianfeng Zhou, Nong Xu, Tian-Shu Liu, Dong Ma, Changping Wu, Ying Cheng, Donghui Chen, Wei Li, San-Yuan Sun, Zhuang Yu, Peiguo Cao, Haihui Chen, Jiejun Wang, Shubin Wang, Hongbing Wang, Ning Wang, Bin Zhang, Qiang Zhang, Weiguo Su, Xiaojun Guo, Jin Li
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. OncoTargets and therapy 14 (2021)
Li Liang, Meng-Ling Liu, Xun Sun, Yitao Yuan, Ke Peng, Khalid Rashid, Yiyi Yu, Yuehong Cui, Yan-Jie Chen, Tian-Shu Liu
Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. Cancer cell international 21 (1) (2021)
Shan Yu, Yan Wang, Xi Cheng, Minzhi Lv, Yuehong Cui, Wei Li, Yiyi Yu, Qian Li, Tian-Shu Liu
Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients. Cancer management and research 12 (2020)
Xiaojing Xu, Yiyi Yu, Minna Shen, Mengling Liu, Shengchao Wu, Li Liang, Fei Huang, Chenlu Zhang, Wei Guo, Tian-Shu Liu
Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. BMC cancer 20 (1) (2020)
Ke Peng, Erbao Chen, Wei Li, Xi Cheng, Yiyi Yu, Yuehong Cui, Qian Li, Yan Wang, Xiaojing Xu, Cheng Tang, Lu Gan, Shan Yu, Tian-Shu Liu
A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer. Journal of cellular physiology 235 (7-8) (2020)
Wei Li, Qian Li, Yiyi Yu, Yan Wang, Erbao Chen, Lingli Chen, Zhiming Wang, Yuehong Cui, Tian-Shu Liu
Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma. Cancer management and research 12 (2020)
Cheng Huang, Qing-Yang Feng, Ye Wei, Li Ren, QingHai Ye, XiaoYing Wang, YueHong Cui, Tian-Shu Liu, Bo Zhou, MingLiang Wang, ShengXiang Rao, Jian Wang, JianYong Ding, Guo-Dong He, Jian-Min Xu
Benefits of multi-disciplinary treatment strategy on survival of patients with colorectal cancer liver metastasis. Clinical and translational medicine 10 (3) (2020)
Er-Bao Chen, Yi-Chou Wei, Hai-Ning Liu, Cheng Tang, Meng-Ling Liu, Ke Peng, Tian-Shu Liu
Hepatoid Adenocarcinoma of Stomach: Emphasis on the Clinical Relationship with Alpha-Fetoprotein-Positive Gastric Cancer. BioMed research international 2019 (2019)
Qian Li, Minzhi Lv, Huiqin Jiang, Yan Wang, Shan Yu, Wei Li, Yiyi Yu, Tian-Shu Liu
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. Journal of cancer research and clinical oncology 146 (1) (2019)
Yiyi Yu, Yong Fang, Zhenbin Shen, Yan Wang, Min Yan, Hui Cao, Yingbin Liu, Xuefei Wang, Yuehong Cui, Fenglin Liu, Weidong Chen, Wei Li, Qian Li, Huiqin Jiang, Yihong Sun, Tian-Shu Liu
Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. The oncologist 24 (10) (2019)
Erbao Chen, Xiaojing Xu, Ruiqi Liu, Tian-Shu Liu
Small but Heavy Role: MicroRNAs in Hepatocellular Carcinoma Progression. BioMed research international 2018 (2018)
Erbao Chen, Xiaojing Xu, Tian-Shu Liu
Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries. Journal of oncology 2018 (2018)
Q Li, H Li, H Jiang, Y Feng, Y Cui, Y Wang, Y Ji, Y Yu, W Li, C Xu, S Yu, R Zhuang, Tian-Shu Liu
Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20 (6) (2017)
Rongyuan Zhuang, Song Li, Qian Li, Xi Guo, Feng Shen, Hong Sun, Tian-Shu Liu
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. PloS one 12 (8) (2017)

Tian-Shu Liu.css-eqlu8i{font-size:small;padding-left:4px;} (TianShu Liu, Tianshu Liu, T Liu)

Publication Activity (10 Years)

Top Topics

Top Venues

Tian-Shu Liu (TianShu Liu, Tianshu Liu, T Liu)